The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback